Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - febuxostat - film-coated tablet - 120 milligram(s) - preparations inhibiting uric acid production; febuxostat

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - febuxostat - film-coated tablet - 80 milligram(s) - preparations inhibiting uric acid production; febuxostat

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

ascend laboratories, llc - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat tablet is a xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. for the safe and effective use of allopurinol, see allopurinol prescribing information. limitations of use: febuxostat tablet is not recommended for the treatment of asymptomatic hyperuricemia. febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)]. risk summary limited available data with febuxostat use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times,

Canada - Tiếng Anh - Health Canada

sanis health inc - febuxostat (febuxostat hemihydrate) - tablet - 80mg - febuxostat (febuxostat hemihydrate) 80mg

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - febuxostat 120mg (as febuxostat hemihydrate) - film coated tablet - 120 mg - active: febuxostat 120mg (as febuxostat hemihydrate) excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 85f32645 purified water - treatment of chronic hyperuricaemia in patients with gout (including a history, or presence of, tophus and/or gouty arthritis). febuxostat is indicated in adults.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - febuxostat 80mg (as febuxostat hemihydrate) - film coated tablet - 80 mg - active: febuxostat 80mg (as febuxostat hemihydrate) excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 85f32645 purified water - treatment of chronic hyperuricaemia in patients with gout (including a history, or presence of, tophus and/or gouty arthritis). febuxostat is indicated in adults.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat 40 mg - uloric is a xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. limitations of use : uloric is not recommended for the treatment of asymptomatic hyperuricemia. uloric is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)] . risk summary limited available data with uloric use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (mrhd). no adverse developmental effects were observed in

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

cardinal health - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat 40 mg - uloric is a xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. for the safe and effective use of allopurinol, see allopurinol prescribing information. limitations of use : uloric is not recommended for the treatment of asymptomatic hyperuricemia. uloric is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)] . risk summary limited available data with uloric use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the m

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

macleods pharmaceuticals limited - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat is a xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. limitations of use: febuxostat is not recommended for the treatment of asymptomatic hyperuricemia. febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)]. risk summary limited available data with febuxostat use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (mrhd). no adverse development

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - febuxostat, quantity: 80 mg - tablet - excipient ingredients: microcrystalline cellulose; hyprolose; croscarmellose sodium; magnesium stearate; silicon dioxide; lactose monohydrate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - treatment of chronic symptomatic hyperuricaemia in conditions where urate deposition has already occurred (gouty arthritis and/or tophus formation) in adults with gout.